It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • PRINT SUBSCRIBERS |
  • SUBSCRIBE |
  • Login
  • My Account
weather icon

8

M/CLOUDY

TOKYO (1 a.m.)

TODAY'S PRINT EDITION

The Japan Times

Daiichi Sankyo

  • Login
  • SUBSCRIBE
  • My Account
  • PRINT SUBSCRIBERS ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Reader Mail
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Japan-made coronavirus vaccines may not be available until 2022

National Dec 4, 2020

Japan-made coronavirus vaccines may not be available until 2022

Only one company in Japan is conducting a trial of a vaccine.

National / Science & Health Aug 31, 2020

Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body

Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development. The vaccine, known as DS-5670, was picked for the second round of AMED's program dedicated ...

Astra to pay Daiichi up to $6 billion for new cancer drug

Business / Corporate Jul 28, 2020

Astra to pay Daiichi up to $6 billion for new cancer drug

AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic.

Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March

National / Science & Health Jun 12, 2020

Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March

The vaccine contains messenger RNA that causes cells to produce proteins that could trigger the body to produce effective antibodies.

Drug devised to replace chemotherapy may reshape cancer care

National / Science & Health Jun 16, 2019

Drug devised to replace chemotherapy may reshape cancer care

by Kanoko Matsuyama

A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care. The complex biological medicines, called antibody drug conjugates ...

AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment

Business / Corporate Mar 29, 2019

AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment

Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.

Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life

Business / Corporate Sep 29, 2017

Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life

by Kanoko Matsuyama

Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer. Now demand is taking off and drugmakers are introducing new products to a ...

Daiichi Sankyo settles U.S. lawsuits over intestinal damage from blood-pressure drugs, paying $300 million

Business / Corporate Aug 2, 2017

Daiichi Sankyo settles U.S. lawsuits over intestinal damage from blood-pressure drugs, paying $300 million

Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines. Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, ...

Business / Corporate May 6, 2016

Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary

Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to ...

Growth concerns loom for Daiichi Sankyo on drug warning

Business / Corporate Feb 9, 2015

Growth concerns loom for Daiichi Sankyo on drug warning

by Kanoko Matsuyama

Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder. The Tokyo-based company's best-selling medicine is set to lose patent protection in ...

Daiichi Sankyo to buy Ambit to strengthen cancer product line

Business / Corporate Sep 29, 2014

Daiichi Sankyo to buy Ambit to strengthen cancer product line

Daiichi Sankyo Co. has agreed to buy U.S.-based Ambit Biosciences Corp. for as much as $410 million to bolster its pipeline of cancer treatments. The Tokyo-based drugmaker will pay $15 in cash per share, it said in a statement Monday to the Tokyo Stock Exchange. Ambit ...

  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Japan can shoot at foreign government vessels attempting to land on Senkakus, LDP official says
    A Chinese marine surveillance ship cruises next to a Japan Coast Guard patrol ship in the East China Sea near the disputed isles known as Senkaku Islands in Japan and Diaoyu Islands in China, in February 2013.
  • Japan to lift state of emergency over COVID-19 in six prefectures from Monday
    People walk in the Minami district of Osaka on Tuesday.
  • ‘Aristocrats’: Power performances capture the world of Japan's elite
    Worlds apart: In “Aristocrats,” Miki (Kiko Mizuhara, left) and Hanako (Mugi Kadowaki) look beyond their completely different backgrounds and learn to admire each other.
  • Japan approves bill simplifying court steps to identify cyberbullies
    Hana Kimura
  • Hong Kong activists find U.K.'s offer of sanctuary comes at a price
    Demonstrators wave the former flag of British Hong Kong during a rally in Hong Kong in 2019.
  • Missing airplane food? Nagoya firm finds success repackaging in-flight meals as bento

    Thumbnail image
  • Kengo Suzuki dethrones Suguru Osako to set new Japan marathon record

    Thumbnail image
  • Left out? Israeli's unvaccinated fear exclusion as economy reopens

    Thumbnail image
  • China expected to unveil hike in military budget as tensions rise

    Thumbnail image
  • Top 5: The sweetest of Tokyo's wagashi offerings

    Thumbnail image
COVID-19 banner

PODCAST

  • DEEP DIVE

    Episode 83: What is Clubhouse and why is it so popular in Japan?

    LAST UPDATED: Feb 24, 2021

JAPAN NETWORK UPDATES

  • Directory of who’s who in the world of business in Japan

    LAST UPDATED: Jun 8, 2020

    JAPAN NETWORK UPDATES
Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha Jobs Study in Japan JT for Women JT Bookclub Japanese School Directory
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Reader Mail
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Privacy Policy
  • Link Policy
  • Reprints
  • FAQs
  • Support
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times